📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-22 17:54
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Solara Shareholders Approve Rs 480 Cr Related Party Transactions with Strides Pharma
Solara Active Pharma Sciences announced the voting results of its 9th Annual General Meeting held on September 18, 2026. All five resolutions were passed with requisite majorities, including the adoption of FY26 financial statements and the reappointment of director Mr. Arun Kumar Pillai. Notably, shareholders approved material related party transactions with Strides Pharma Science Limited for up to Rs 480 crore, which represents approximately 33.5% of Solara's TTM revenue of Rs 1,431 crore. In this resolution, interested promoter entities abstained, and 99.87% of the 78.04 lakh polled public votes were cast in favor.
Confidence: HIGH
What changedShareholders officially passed all 9th AGM resolutions, including setting an operational transaction ceiling of Rs 480 crore with Strides Pharma Science Limited.
Why it mattersEnables continued commercial supply and service agreements with promoter-linked entity Strides Pharma, representing over a third of Solara's annual revenue base.
Strides RPT limit: Rs 480 croreRPT limit vs TTM revenue: ~33.5%Total shareholders on record date: 71,549RPT approval in-favor vote %: 99.8684%
📅 Short termRoutine administrative closure of the AGM; minimal immediate impact on share price trading.
📈 Long termSecures the contractual runway for operational collaboration with Strides Pharma, maintaining regular API revenue channels.
⚠ Risk flags
- High related-party operational exposure (up to Rs 480 crore transaction cap).
Key Highlights
Approved material related party transactions with Strides Pharma Science Limited up to Rs 480 crore.
Strides RPT approval received 99.87% votes in favor among public shareholders, with promoter group abstaining from voting.
Reappointed Mr. Arun Kumar Pillai as Non-Executive Director with 99.96% votes in favor.
Adopted standalone and consolidated financial statements for the fiscal year ended March 31, 2026.
Overall meeting attendance recorded 59 shareholders via video conferencing (15 promoter and 44 public).
👀 What to Watch
Track the execution and quarterly disclosures of supply arrangements with Strides Pharma Science to monitor business volume realization relative to the Rs 480 crore ceiling.
Solara Active Pharma: ₹161.92 Cr Tax Demand Dropped to Nil via Rectification Order
Solara Active Pharma Sciences has received a Rectification Order under Section 154 of the Income Tax Act from the IT Department for Assessment Year 2019-20. The order rectifies a previous computation error and completely drops an earlier tax demand of ₹161.92 crore down to Nil. This eliminates a substantial contingent tax overhang equivalent to ~17.5% of the company's market capitalization (₹924 crore) and ~12.9% of its net worth (₹1,256 crore). There are no adverse penalties, non-compliances, or financial impacts remaining from this demand.
Confidence: HIGH
What changedThe Income Tax Department has rectified an erroneous computation, reducing a ₹161.92 crore tax demand for AY 2019-20 to Nil.
Why it mattersEliminates a major potential cash outflow/liability overhang representing ~17.5% of Solara's market capitalization without any financial penalty or liability.
Dropped tax demand: Rs. 161.92 CroresDemand vs Market Cap: ~17.5%Demand vs Net Worth: ~12.9%Applicable Assessment Year: Assessment Year 2019-20
📅 Short termPositive sentiment driver as a significant disputed tax liability is fully cleared with zero cash outflow.
📈 Long termClears balance sheet contingent risk; operational focus remains on API business recovery and utilization of facilities like Vizag.
Key Highlights
Income Tax rectification order reduces tax demand of ₹161.92 crore to Nil
Relates to Assessment Year 2019-20 Demand Notice originally received on March 17, 2026
Order passed under Section 154 read with Section 147 by Assistant Commissioner of Income Tax, Thane
Demand of ₹161.92 crore represented ~17.5% of market capitalization (₹924 Cr)
👀 What to Watch
Monitor subsequent quarterly filings for confirmation that contingent liability disclosures reflect the cancellation of this ₹161.92 crore tax dispute.
Solara Q1 FY27: PAT up 55% to ₹16.3 Cr; Net Debt reduced by 22% to ₹479 Cr
Solara reported its highest EBITDA and PAT in 18 quarters for Q1 FY27, with total revenue growing 20% YoY to ₹384 Cr. The turnaround is driven by the base business (non-Ibuprofen), which grew 24% YoY to ₹307 Cr with gross margins exceeding 52%. A critical development is the ₹135 Cr reduction in net debt, bringing it down to ₹479 Cr (1.9x annualized EBITDA), largely funded by ₹100 Cr from a rights issue. However, the Ibuprofen segment remains a drag with a negative 12% EBITDA margin due to pricing and supply chain pressures.
Confidence: HIGH
What changedSolara has achieved its most profitable quarter in 4.5 years and significantly deleveraged its balance sheet using rights issue proceeds and operational cash flow.
Why it mattersThe reduction in net debt to 1.9x EBITDA and the strong performance of the high-margin base business indicate a successful initial phase of the company's turnaround strategy.
Q1 FY27 Revenue: ₹384 CrQ1 FY27 PAT: ₹16.3 CrNet Debt: ₹479 CrDebt Reduction vs TTM Net Worth: ~10.7%Base Business Gross Margin: 52%Net Debt/EBITDA (Annualized): 1.9x
📅 Short termThe stock may react positively to the significant debt reduction and the highest quarterly profit in several years.
📈 Long termThe long-term outlook depends on the successful scaling of the CRAMS business and resolving the profitability issues in the commodity Ibuprofen segment.
⚠ Risk flags
- Negative margins in Ibuprofen segment
- Raw material price volatility due to West Asia crisis
- Limited working capital
Key Highlights
Q1 FY27 PAT reached ₹16.3 Cr, a 55% YoY increase and the highest in 18 quarters.
Net debt reduced by ₹135 Cr (22%) during the quarter to ₹479 Cr as of June 30, 2026.
Base business revenue grew 24% YoY to ₹307 Cr, maintaining a healthy 52% gross margin profile.
Ibuprofen business reported a negative 12% EBITDA margin, though showing marginal sequential improvement.
Management targets further debt reduction to approximately ₹440 Cr by March 2027.
👀 What to Watch
Watch for the strategic decision on the Ibuprofen business expected by the end of H1 FY27 and the company's ability to sustain 10% growth in the base business amidst raw material price volatility.
₹16.3 Cr PAT; Solara Reports Highest Quarterly Profit in 18 Quarters for Q1 FY27
Solara reported a strong Q1 FY27 with overall revenue growing 20% YoY to ₹384.3 Cr and PAT reaching ₹16.3 Cr, the highest in 18 quarters. The performance was driven by the Base Business (ex-Ibuprofen), which grew 24% YoY, while the Ibuprofen segment continued to drag with an EBITDA loss of ₹8.7 Cr. A significant debt reduction of ₹134.6 Cr was achieved during the quarter, primarily through a rights issue and internal accruals. Management is currently evaluating strategic options for the loss-making Ibuprofen business, with a decision expected by Q2 FY27.
Confidence: HIGH
What changedThe company has achieved a multi-year high in profitability and significantly deleveraged its balance sheet using rights issue proceeds and operational cash flows.
Why it mattersThis marks a potential turnaround for Solara, addressing two major investor concerns: high debt levels and the margin-dilutive nature of the commodity Ibuprofen business.
Q1 FY27 Revenue: ₹384.3 CrQ1 FY27 PAT: ₹16.3 CrDebt Reduction in Q1: ₹134.6 CrNet Debt to EBITDA: 1.9xQ1 Revenue vs TTM Revenue: ~28%
📅 Short termThe stock is likely to react positively to the 'highest profit in 18 quarters' headline and the visible reduction in debt.
📈 Long termStructural improvement depends on the successful resolution of the Ibuprofen business and the scaling of the CRAMS and non-Ibuprofen API portfolio.
⚠ Risk flags
- Continued EBITDA losses in the Ibuprofen segment
- Input cost pressures due to geopolitical developments in West Asia
- High dependency on regulated market approvals (75%+ of revenue)
Key Highlights
Overall PAT of ₹16.3 Cr marks the highest profitability reported in the last 18 quarters.
Net debt reduced by ₹134.6 Cr during the quarter, bringing total net debt down to ₹479.5 Cr.
Base business (ex-Ibuprofen) revenue grew 24% YoY to ₹307.7 Cr with a 23.5% EBITDA margin.
Ibuprofen business remains a drag with an EBITDA loss of ₹8.7 Cr and a negative 11.4% margin.
Net Debt to EBITDA ratio improved to 1.9x (annualized) from 2.5x in FY26.
👀 What to Watch
Watch for the management's strategic decision regarding the Ibuprofen business by the end of Q2 FY27, as a potential carve-out or sale could significantly re-rate overall margins.
Solara Board Approves Q1 FY27 Results; Targets Quarterly Revenue of ₹350 Cr+
Solara Active Pharma Sciences has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently attempting to pivot from a stable phase to a growth phase, specifically targeting consistent quarterly revenues of ₹350 Cr+. While the specific Q1 figures were not detailed in the cover letter, the company entered this period following a profitable March 2026 quarter (₹9.73 Cr PAT) after two consecutive loss-making quarters. Investors should focus on whether the operating profit margin (TTM 13.6%) is recovering toward the FY25 level of 16.1%.
Confidence: HIGH
What changedThe company has finalized and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a company with a TTM net loss of ₹7 Cr and a debt-to-equity ratio of 0.51, consistent quarterly profitability is essential to support its valuation and debt servicing capabilities.
Target Quarterly Revenue: ₹350 Cr+TTM Revenue: ₹1369 CrTotal Debt: ₹637 CrDebt to TTM Revenue: 0.46Promoter Holding: 42.0%
📅 Short termThe stock price may react based on whether the Q1 revenue and margins met the company's internal growth-phase targets of ₹350 Cr+ per quarter.
📈 Long termStructural recovery depends on the successful expansion of the CRAMS business and managing price competition from Chinese suppliers to maintain a 51% gross margin profile.
⚠ Risk flags
- Sensitivity to Chinese price competition
- High inventory levels (estimated >120 days)
- Regulatory risks (US FDA Import Alerts/Warning Letters)
Key Highlights
Board meeting held on July 23, 2026, concluded within 65 minutes (12:00 PM to 1:05 PM).
Company is targeting a quarterly revenue run-rate of ₹350 Cr+ to sustain its growth strategy.
TTM revenue stands at ₹1,369 Cr against a total debt of ₹637 Cr.
Regulated markets currently contribute approximately 75% of the company's total revenue.
Statutory auditors Deloitte Haskins & Sells completed the Limited Review for the quarter ended June 30, 2026.
👀 What to Watch
Review the detailed quarterly P&L to check if revenue exceeded the ₹350 Cr target and monitor the status of the 'mothballed' Vizag facility, which requires CRAMS partnerships to resume operations.
CRISIL Upgrades Solara Active Pharma's Credit Rating for Rs 791.2 Cr Bank Facilities
CRISIL Ratings has upgraded Solara Active Pharma Sciences Limited's long-term credit rating to 'CRISIL BBB+/Stable' from 'CRISIL BBB/Stable'. Simultaneously, the short-term rating has been upgraded to 'CRISIL A2' from 'CRISIL A3+'. This rating action covers total bank loan facilities amounting to Rs 791.2 crore. The upgrade reflects an improvement in the company's credit profile and financial stability as assessed by the rating agency.
Key Highlights
Long-term rating upgraded to CRISIL BBB+/Stable from CRISIL BBB/Stable.
Short-term rating upgraded to CRISIL A2 from CRISIL A3+.
Total bank loan facilities covered by the rating amount to Rs 791.2 crore.
Major credit facilities include Rs 170 crore from HDFC Bank and Rs 146.5 crore from IDFC FIRST Bank.
The rating remains valid until March 31, 2027, under continuous surveillance.
👀 What to Watch
The credit upgrade is a positive indicator of improving financial health and may lead to reduced interest costs for the company. Investors should consider this a sign of reduced default risk and strengthening fundamentals.
Solara Q4 FY26: EBITDA Surges 65% Q-o-Q to ₹61 Cr; Ibuprofen Strategic Review Underway
Solara reported a strong Q4 FY26 with revenue growing 12% Q-o-Q to ₹392 crores and EBITDA jumping 65% to ₹61 crores, driven by a high-margin base business. While the base business operates at a robust 26% EBITDA margin, the Ibuprofen segment remains a drag with negative EBITDA, leading the board to appoint bankers for a strategic review expected to conclude in H1 FY27. The company successfully reduced debt by ₹158 crores (21%) during FY26 and expects further reduction to ₹503 crores following the second call of its rights issue. Management highlighted that capacity utilization stands at 70%, providing room for growth without significant immediate capex.
Key Highlights
Revenue grew 12% Q-o-Q to ₹392 crores, marking the highest performance in the last 8 quarters.
EBITDA increased 65% Q-o-Q to ₹61 crores with overall margins expanding to 16%.
The base business (excluding Ibuprofen) demonstrated superior profitability with 26% EBITDA margins and 54% gross margins.
Net debt was reduced by ₹158 crores in FY26, a 21% decrease, with a target to reach ₹503 crores by May 2026.
Bankers have been appointed to evaluate strategic options for the loss-making Ibuprofen business, with a conclusion expected in H1 FY27.
👀 What to Watch
Investors should monitor the outcome of the Ibuprofen strategic review in H1 FY27 as a potential re-rating catalyst. The strong performance of the base business and significant debt reduction are positive indicators of a successful operational turnaround.
Solara Reports Zero Deviation in ₹309.79 Cr Rights Issue Fund Utilization
Solara Active Pharma Sciences has confirmed zero deviation in the utilization of proceeds from its Rights Issue for the quarter ended March 31, 2026. The company has raised a total of ₹309.79 crores to date, which includes ₹155.31 crores collected from the first call money. The majority of the funds have been deployed toward debt repayment (₹233.61 crores) and general corporate purposes (₹74.97 crores). As of the reporting date, only ₹1.20 crores remain unutilized in the monitoring agency account.
Key Highlights
Total funds raised via Rights Issue as of March 31, 2026, reached ₹309.79 crores.
₹233.61 crores utilized for repayment or pre-payment of outstanding borrowings.
₹74.97 crores utilized for General Corporate Purposes (GCP) out of an allocated ₹112.24 crores.
First Call money raised amounted to ₹155.31 crores, with ₹154.10 crores already deployed.
Audit Committee confirmed no deviations or variations from the objects stated in the Letter of Offer.
👀 What to Watch
Investors should view the disciplined utilization of funds for debt reduction as a positive sign for the company's balance sheet health. No immediate action is required as the company is adhering to its disclosed capital allocation strategy.
Solara Active Pharma Collects Rs 129.94 Cr via Final Call on Rights Issue Shares
Solara Active Pharma Sciences has successfully received Rs 129.94 crore as the second and final call money for its rights issue. This payment pertains to 1,15,50,478 shares, which have now been converted from partly paid-up to fully paid-up equity shares. The call money consisted of Rs 3.00 towards face value and Rs 109.50 towards securities premium per share. The company is now proceeding with listing and trading approvals for these converted shares, strengthening its equity base and completing the capital raising cycle.
Key Highlights
Received total call money of Rs 129,94,28,775 for 1,15,50,478 rights equity shares
Final call amount was Rs 112.50 per share, including a securities premium of Rs 109.50
Converted 1.15 crore shares from Rs 7 paid-up to Rs 10 fully paid-up equity shares
Total fully paid-up equity shares now stand at 4,77,25,485
Company to seek listing and trading approvals for the newly converted fully paid-up shares
👀 What to Watch
Investors should monitor the listing of these new fully paid-up shares which will increase the tradeable float. The successful completion of the rights issue fundraise provides the company with necessary capital for its strategic objectives.
Solara Q4 FY26 Revenue Jumps 40% YoY to ₹3,919mn; Base Business EBITDA Margin Hits 26%
Solara reported a strong Q4 FY26 with revenue growing 40% YoY to ₹3,919 million, marking its highest performance in eight quarters. The core 'Base Business' showed significant strength with a 26% EBITDA margin, while the commodity Ibuprofen segment remained a drag with a negative 21% EBITDA margin. Consequently, the company has appointed bankers to explore strategic options for the Ibuprofen business to unlock value. Net debt is on a downward trajectory, expected to reach approximately ₹5,030 million by May 2026 following rights issue proceeds.
Key Highlights
Q4 FY26 Revenue grew 40% YoY to ₹3,919 million, with PAT turning positive at ₹96 million.
Base business (excluding Ibuprofen) delivered robust margins with 54% Gross Margin and 26% EBITDA Margin.
Ibuprofen business remains a drag with a negative EBITDA of ₹179 million and a negative 21.1% margin in Q4.
Net debt reduced from ₹7,719 million in Mar'25 to ₹6,141 million in Mar'26, with a target of ₹5,030 million by May'26.
Board has initiated a strategic review of the Ibuprofen business, appointing bankers to evaluate divestment or other options.
👀 What to Watch
Investors should monitor the strategic review of the Ibuprofen business as a potential exit from this loss-making segment could significantly re-rate the stock. The strong 26% EBITDA margin in the base business indicates a healthy underlying API portfolio.
Solara Active Pharma Reports FY26 Results; Auditors Issue Unmodified Opinion on Net Loss
Solara Active Pharma Sciences approved its audited financial results for the fiscal year ended March 31, 2026, in a board meeting held on May 15, 2026. The company reported a consolidated net loss for the year, although the statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the financial statements. The group's structure evolved during the year with the addition of Synthix Global Pharma Solutions Limited as a wholly-owned subsidiary effective April 29, 2025. Investors should note that while the reporting is transparent, the company remains in a loss-making position on a consolidated basis.
Key Highlights
Board approved audited consolidated and standalone financial results for the full year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the fairness of the reported consolidated net loss.
Incorporation of Synthix Global Pharma Solutions Limited as a new wholly-owned subsidiary during the fiscal year.
The consolidated results include the performance of four entities: the Parent, Shasun USA Inc., Chemsynth Laboratories, and Synthix Global.
The Board meeting was conducted efficiently, commencing at 12:00 PM and concluding at 12:50 PM.
👀 What to Watch
Investors should scrutinize the full financial statements to identify the specific drivers behind the consolidated net loss and assess the company's path to profitability. Monitor the contribution of the newly formed subsidiary, Synthix Global, in upcoming quarterly reports.
Solara Receives US FDA EIR for Puducherry Facility with VAI Classification
Solara Active Pharma Sciences has successfully closed a US FDA inspection at its Puducherry Ibuprofen manufacturing facility. The unannounced inspection, conducted between February 2 and February 6, 2026, initially resulted in four procedural Form 483 observations. Following the company's timely response, the US FDA issued an Establishment Inspection Report (EIR) on April 24, 2026, classifying the facility as Voluntary Action Indicated (VAI). This closure confirms continued cGMP compliance and secures the regulatory standing of a key site catering to international markets.
Key Highlights
Successful closure of US FDA inspection at the Puducherry Ibuprofen manufacturing site
Received Establishment Inspection Report (EIR) with 'Voluntary Action Indicated' (VAI) status on April 24, 2026
Inspection conducted from Feb 2 to Feb 6, 2026, resulted in 4 procedural Form 483 observations
The Puducherry site is a core facility approved by multiple global agencies including US FDA, EDQM, and MHRA
👀 What to Watch
Investors should view this as a significant positive development that removes regulatory overhang on a key manufacturing asset. The successful EIR receipt validates the company's quality systems and ensures uninterrupted supply to the US market.
Solara Pharma Announces Final Call of ₹112.50 per Rights Share; Record Date April 2, 2026
Solara Active Pharma Sciences has approved the second and final call for its partly paid-up rights shares. Shareholders holding these shares as of the record date, April 2, 2026, will be required to pay ₹112.50 per share. This payment consists of ₹3.00 towards face value and ₹109.50 towards securities premium. This procedural step completes the capital raising process initiated via the rights issue in May 2024.
Key Highlights
Second and final call amount set at ₹112.50 per equity share.
Record date for identifying eligible partly-paid shareholders is April 02, 2026.
Call price breakdown: ₹3.00 face value and ₹109.50 securities premium per share.
Relates to the rights issue originally offered via the Letter of Offer dated May 09, 2024.
👀 What to Watch
Investors holding partly paid shares (SOLARAPP1) must pay the final call amount to convert them into fully paid shares. Failure to pay by the specified deadline will lead to the forfeiture of the shares and the initial investment.
Solara Active Pharma Sets April 2 Record Date for ₹112.50 Final Call on Rights Shares
Solara Active Pharma Sciences has scheduled the second and final call for its partly-paid rights shares issued in 2024. The company has fixed April 02, 2026, as the record date to identify shareholders liable for the payment. Investors must pay ₹112.50 per share, which consists of ₹3.00 towards face value and ₹109.50 towards securities premium. This final payment will convert the partly-paid shares into fully-paid equity shares of the company.
Key Highlights
Final call amount fixed at ₹112.50 per equity share for partly-paid rights shares.
Record date for determining eligible shareholders is set for April 02, 2026.
Call price includes ₹3.00 face value and ₹109.50 securities premium per share.
The call is pursuant to the Rights Issue Letter of Offer dated May 09, 2024.
Successful payment will result in the conversion of partly-paid shares to fully-paid equity.
👀 What to Watch
Investors holding partly-paid shares (SOLARAPP1) should ensure they have sufficient liquidity to meet the ₹112.50 per share call to avoid the risk of share forfeiture. Failure to pay the final call will lead to the loss of the initial investment made during the rights issue.
Solara Active Pharma Announces Final Call of ₹112.50 per Rights Share; Record Date April 02
Solara Active Pharma Sciences has approved the second and final call for its partly paid-up rights shares. Shareholders holding these shares are required to pay ₹112.50 per share, which includes ₹3.00 for face value and ₹109.50 for securities premium. The company has established April 02, 2026, as the record date to determine eligible holders for the call notice. This final payment is the concluding step in the rights issue process initiated in May 2024 to convert partly paid shares into fully paid equity.
Key Highlights
Final call amount set at ₹112.50 per rights share
Record date for determining eligible shareholders is April 02, 2026
Call amount comprises ₹3.00 face value and ₹109.50 securities premium
Process follows the Rights Issue Letter of Offer dated May 09, 2024
👀 What to Watch
Investors holding partly paid shares (SOLARAPP1) must pay the final call amount within the specified timeline to avoid forfeiture of their shares. Ensure funds are available before the payment window opens following the record date.
Solara Active Pharma Receives ₹161.92 Crore Income Tax Demand Notice
Solara Active Pharma Sciences has received a significant tax demand notice of ₹161.92 Crores from the Income Tax Department for the Assessment Year 2019-20. The demand stems from the disallowance of certain expenses claimed by the company in its tax filings. The company has stated its intention to file an appeal against this order before the relevant Appellate Authority. Management believes the case has merit and does not currently expect a material financial impact, though the amount is substantial.
Key Highlights
Received a Tax Demand Notice of ₹161.92 Crores under Section 156 of the Income Tax Act, 1961.
The demand pertains to Assessment Year 2019-20 following an audit of claimed expenses.
The order was passed by the Deputy Commissioner of Income Tax, Central Circle-3, Thane.
Company plans to contest the demand by filing an appeal with the Appellate Authority.
Management maintains that there will be no material financial impact due to the merits of their case.
👀 What to Watch
Investors should monitor the legal proceedings as the demand amount is significant relative to the company's financials. While the company is contesting, any unfavorable final ruling could impact cash flows.
Solara Shareholders Approve Mohanraj Sanjeevi as Whole-time Director with 99.97% Majority
Solara Active Pharma Sciences Limited has announced the successful passage of a special resolution to appoint Mr. Mohanraj Sanjeevi as a Whole-time Director for a three-year term. The resolution received overwhelming support, with 99.97% of the 26.04 million votes cast in favor. Mr. Sanjeevi's remuneration is set at a fixed Rs. 85 lakh per annum plus a variable component of Rs. 15 lakh. This appointment, effective from January 1, 2026, ensures leadership stability for the company's executive operations.
Key Highlights
Special resolution for appointment passed with 99.97% majority (26,032,102 votes in favor).
Mr. Mohanraj Sanjeevi appointed for a 3-year term effective from January 1, 2026, to December 31, 2028.
Total annual remuneration package includes Rs. 85 lakh fixed and Rs. 15 lakh variable pay.
Promoter and institutional investor groups both voted 100% in favor of the resolution.
Overall voter turnout represented 58.64% of the total outstanding shares of the company.
👀 What to Watch
The high level of shareholder support indicates strong confidence in the executive leadership. Investors should view this as a routine governance step providing management continuity.
Solara Q3 FY26: Growth API Margins at 25% Amid Strategic Review of Ibuprofen Business
Solara reported Q3 FY26 revenue of INR 346 crores, up 10% Q-o-Q, though consolidated gross margins fell to 47% due to headwinds in the base ibuprofen business. The non-ibuprofen 'growth' segment is performing exceptionally well with 56% gross margins and 25% EBITDA margins, significantly outperforming the commodity business. Management has initiated a strategic review of the ibuprofen division, which is currently utilizing only 3,000 tons of its 6,000-ton Pondicherry capacity. The company successfully reduced debt by INR 146 crores (19%) and targets a sub-INR 500 crore debt level by May 2026.
Key Highlights
Revenue grew 10% Q-o-Q to INR 346 crores; EBITDA stood at INR 37 crores with an 11% margin.
Non-ibuprofen growth business achieved high-tier margins of 56% (gross) and 25% (EBITDA).
Ibuprofen capacity utilization remains low at 50% for the Pondicherry plant (3,000 of 6,000 tons).
Debt was reduced by INR 146 crores (19%) during the quarter, aided by rights issue proceeds.
A one-time exceptional cost of INR 6.7 crores was incurred due to the new labor wage code implementation.
👀 What to Watch
Investors should closely monitor the Q4 announcement regarding the strategic review of the ibuprofen business, as a potential restructuring or hive-off could unlock significant value from the high-margin growth API segment.
Solara Reports Zero Deviation in ₹308.85 Cr Rights Issue Fund Utilization
Solara Active Pharma Sciences has confirmed that there is no deviation or variation in the utilization of ₹308.85 crores raised through its Rights Issue as of December 31, 2025. The company has primarily used the proceeds for debt reduction, with ₹233.61 crores allocated to the repayment or pre-payment of borrowings. Additionally, ₹74.97 crores have been utilized for general corporate purposes out of a total planned allocation of ₹112.24 crores. The Audit Committee and monitoring agency CRISIL have reviewed and approved these statements without any adverse comments.
Key Highlights
Total funds raised through the Rights Issue amounted to ₹308.85 crores as of December 31, 2025.
A significant portion of ₹233.61 crores was utilized for the repayment or pre-payment of outstanding borrowings.
₹74.97 crores were deployed for General Corporate Purposes (GCP), adhering to the 25% cap of gross proceeds.
The company reported zero deviation from the objects mentioned in the Letter of Offer dated May 09, 2024.
A minor balance of ₹0.26 crores remains in the escrow account to be utilized in upcoming quarters.
👀 What to Watch
Investors should take confidence in the company's disciplined use of capital for debt reduction, which should improve the balance sheet. Monitor upcoming earnings reports to see the positive impact of reduced interest costs on the bottom line.
Solara Q3 FY26 Revenue Up 15% to ₹3,490M; Board to Evaluate Ibuprofen Business Options
Solara reported a 15% YoY revenue growth to ₹3,490 million in Q3 FY26, driven by its high-margin Growth API segment which achieved a 24.7% EBITDA margin. However, the company posted a net loss of ₹174 million as the commodity Ibuprofen business remains a significant drag with negative EBITDA margins of -22.9%. To address this structural challenge, the Board is appointing strategic advisors to evaluate options for the Ibuprofen business and re-assess the previously announced CRAMS split. Debt reduction is on track, with gross debt falling to ₹6,300 million from ₹7,760 million in March 2025.
Key Highlights
Revenue grew 15% YoY to ₹3,490 million, though EBITDA fell 37% YoY to ₹374 million due to Ibuprofen pricing pressures.
Growth API segment (Ex-Ibuprofen) delivered strong performance with 56.3% gross margins and ₹608 million EBITDA.
Ibuprofen base business reported an EBITDA loss of ₹234 million for the quarter, prompting a strategic review.
Gross debt reduced to ₹6,300 million as of December 2025, with a target to reach ₹4,999 million by May 2026.
Board is re-evaluating the CRAMS & Polymers business split scheme with a new roadmap expected next quarter.
👀 What to Watch
Investors should closely monitor the upcoming strategic roadmap for the Ibuprofen business, as a potential divestment or restructuring could unlock value by isolating the high-growth, high-margin API portfolio.
